<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">HAN, GWAN HEE</style></author><author><style face="normal" font="default" size="100%">KIM, JULIE</style></author><author><style face="normal" font="default" size="100%">YUN, HEE</style></author><author><style face="normal" font="default" size="100%">CHO, HANBYOUL</style></author><author><style face="normal" font="default" size="100%">CHUNG, JOON-YONG</style></author><author><style face="normal" font="default" size="100%">KIM, JAE-HOON</style></author><author><style face="normal" font="default" size="100%">HEWITT, STEPHEN M.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">&lt;em&gt;CRY1&lt;/em&gt; Regulates Chemoresistance in Association With &lt;em&gt;NANOG&lt;/em&gt; by Inhibiting Apoptosis &lt;em&gt;via STAT3&lt;/em&gt; Pathway in Patients With Cervical Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Genomics - Proteomics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">699-713</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/cgp.20291</style></doi><volume><style face="normal" font="default" size="100%">18</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Cryptochrome 1 (CRY1), a core circadian gene, modulates circadian rhythm and carcinogenesis. Here, we investigated the role of CRY1 and its correlation with NANOG, a stem cell transcription factor, in cervical cancer. Materials and Methods: Immunohistochemistry with tissue microarray was performed to evaluate CRY1 and NANOG expression in cervical cancer tissues, and their functional roles were assessed in cervical cancer cell lines. Results: CRY1 or NANOG was significantly over-expressed in cervical cancer tissues. Notably, combined over-expression of CRY1 and NANOG was correlated with a significantly poor OS and DFS and showed a stronger predictive value for chemoradiation response than each single protein. Furthermore, siCRY1 induced apoptosis, decreased NANOG expression, suppressed STAT3 signalling, and activated p53 signalling in cervical cancer cell lines. Conclusion: CRY1 and NANOG over-expression serves as a strong predictive biomarker for prognosis and chemoradiation response, and may be a new therapeutic target in patients with cervical cancer.</style></abstract></record></records></xml>